ArticleMovement disorders : official journal of the Movement Disorder Society2025
Distinct AQP4 Alterations in Movement Disorders with Primary Synucleinopathy.
Article in Movement disorders : official journal of the Movement Disorder Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Recognizing Alzheimer's disease and Parkinson's disease as astrogliopathies.Neural regeneration research · 2026Article
- Convergent Astrocytic Failure in Parkinson's Disease: A System-Level Model of Pathogenesis and Treatment.Molecular neurobiology · 2026Review
- The Glymphatic System in α-Synucleinopathies.Yonsei medical journal · 2026Review
- Divergent Glymphatic Dysfunction and Free Water Pathology Underpin Distinct Mechanisms and Enable Differential Diagnosis in Parkinson's Disease and Multiple System Atrophy.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Alpha-Synuclein in Neurodegeneration: From Shared Biology to Disease-Specific Phenotypes.Cells · 2026Review
- Transcriptomic profiling and targeted validation reveal molecular mechanisms of oxygen therapy in high-altitude cerebral injury.Frontiers in neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAquaporin-4 (AQP4) is involved in clearing amyloidogenic proteins, but it remains unexplored how it is comparatively altered in neuron- and oligodendrocyte-predominant synucleinopathies.
objectiveThe aim was to assess AQP4 protein localization and abundance in Parkinson's disease (PD) and multiple system atrophy (MSA).
methodsThe motor cortex and subcortical white matter of PD (n = 29), MSA (n = 19), and controls (n = 17) were immunohistochemically analyzed.
resultsIn normal aging, neuritic plaques caused an increase in AQP4 abundance without altering polarization. Arteriolosclerosis and immunosuppressant medications had no impact. AQP4 endfeet recruitment decreased in early PD but recovered in late PD by enhanced polarization. AQP4 was depolarized in MSA-parkinsonian type, but unaffected in MSA-cerebellar type, with both preserved AQP4 endfeet recruitment. In controls with neuritic plaques and PD, AQP4 changes were predominantly in superficial cortical layers, with no regional preference in MSA.
conclusionThe distinct AQP4 changes in neuronal and glial synucleinopathies underscore different pathomechanisms, warranting further investigation. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.